Innate Pharma Sa Class A · EURONEXT:IPH
Innate Pharma Sa Class A — SITC 2018 (Society for Immunotherapy of Cancer Annual Meeting)
15 slides from Innate Pharma Sa Class A's conference presentation, November 2018
Slide 1: SITC 2018 Annual Meeting
‘2018 ~S@ NOVEMBER 7-11 WASHINGTON, D.C. Walter E. Washington Convention Center sitc > Society for Immunotherapy of Cancer #SITC2018
Slide 2: Monalizumab in combination with cetuximab in R/M SCCHN: Clinical results and preliminary biomarker analyses
Monalizumab in combination with cetuximab in R/M SCCHN: Clinical results and preliminary biomarker analyses. Roger B. Cohen1, Jérôme Fayette2, Marshall Posner3, Gautier Lefebvre4, Jessica Bauman5, Sébastien Salas6, Caroline Even7, Dimitrios Colevas8, Antonio Jimeno9, Esma Saada10, Barbara Burtness11
Slide 3: Presenter Disclosure Information
Presenter Disclosure Information Roger B. Cohen, MD The following relationships exist related to this presentation: • Advisory board member with honoraria: Genocea, Innate • Funding to institution for research support: Celldex, Genocea, Innate, Macrogenics , Merck • Uncompensated advisory role: Cell
Slide 4: Dual antibody targeting in cancer immunology
Dual antibody targeting in cancer immunology Monalizumab blocks NKG2A/HLA-E inhibitory pathway unleashing NK and T cell activity Monalizumab: • First-in-class humanized IgG4 Monalizumab targeting NKG2A on NK and NK HLA-E NKG2A tumor infiltrating CD8+ T cells. cell Inhibition Tumor cell • Blocks bind
Slide 5: IPH2201-203 study design
IPH2201-203 study design • Multicenter single arm study to evaluate the combination of monalizumab and cetuximab in patients with recurrent and/or metastatic SCCHN (R/M SCCHN) • Cohort expansion in recurrent and/or metastatic SCCHN patients (NCT02643550). • N= 40 patients enrolled. Data cut-off Augu
Slide 6: Key Baseline characteristics
Key Baseline characteristics Characteristics (N=40) N (%) Previous treatment (N=40) N (%) Age Median [range] 64 [34-76] 1 20 (50%) Female 12 (30%) 2 13 (33%) Sex >3 7 (18%) Male 28 (70%) 0 14 (35%) Prior platinum 40 (100%) ECOG platinum resistant** 21 (53%) 1 26 (65%) platinum sensitive 19 (48%) Pri
Slide 7: Objective responses with monalizumab and cetuximab
Objective responses with monalizumab and cetuximab Best change of tumor size from baseline Overall Response Rate is 27.5% [95% CI, 16.1-42.8] 1 confirmed CR & 10 confirmed PR Responses observed in IO naive (35% [19-55]) and IO pretreated patients (18% [6-41]) Responses observed in platinum resis
Slide 8: Early and Durable responses with monalizumab and cetuximab
Early and Durable responses with monalizumab and cetuximab Change of tumor size from baseline *: Prior IO c: Prior cetuximab Median time to response is 1.6 months [1.5-3.9] Median duration of response is 5.6 months [3.8-NR*] *NR = Not Reached
Slide 9: PFS and OS in all patients and according to prior IO
PFS and OS in all patients and according to prior IO PFS in all patients PFS according to prior IO OS in all patients OS according to prior IO
Slide 10: Safety profile of the combination
Safety profile of the combination AEs related to the monalizumab cetuximab combination All TEAEs Monalizumab related TEAEs N (%) N (%) All Grade 3-4 All Grade 3-4 40 20 30 7 AEs (100%) (50%) (75%) (18%) 16 12 3 3 SAEs (40%) (30%) (8%) (8%) • No new safety signals for monalizumab • Only one patient s
Slide 11: Preliminary PK, immunogenicity and PD
Preliminary PK, immunogenicity and PD • At 10 mg/kg every 2 weeks monalizumab concentration remained well above 20 µg/mL preclinical target concentration in all patients. • Cetuximab administration had no impact on monalizumab PK. • No clinically significant immunogenicity was observed in this study
Slide 12: Preliminary biomarker results summary
Preliminary biomarker results summary • CD16 polymorphism was not found predictive of response in this cohort. • High HLA-E expression was observed in all analyzed tumor samples - not predictive of response in this cohort of patients. • Stromal NK cell (NKP46+ cells) and tumor CD8+ T cell infiltrati
Slide 13: Infiltration of CD8+ T cells and NK cells 15 days after first administration
CD8+ stromal Lymphocyte Proportion Score Infiltration of CD8+ T cells and NK cells 15 days after first administration of monalizumab and cetuximab in responding patients PFS and OS by CD8+ stromal Lymphocyte Proportion Score difference* CD8+ NKp46+ Baseline CD8+ NKp46+ 15 days after first administra
Slide 14: Conclusions
Conclusions • The combination of monalizumab and cetuximab results in early, deep and durable responses in patients with R/M SCCHN • Encouraging PFS and OS in both IO naïve and IO pretreated patients • Combination has activity in platinum-resistant, HPV positive and negative patients • Activity appe
Slide 15: Acknowledgement
Acknowledgement • We thank the patients who participated in the IPH2201-203 study and their families • The referring physicians, co-investigators and clinical study site staff at the participating institutions • The study is sponsored by Innate Pharma and supported by AZ/MedImmune
Innate Pharma — SITC 2018 (Society for Immunotherapy of Cancer Annual Meeting) on 6ix